MedTrace Logo

Correlation Between Plasma- and Endothelial DPP-4 Activity

NCT02192853 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-09-11

No results posted yet for this study

Summary

The investigators want to estimate both the endothelial and the plasma activity of dipeptidyl peptidase 4 during different doses of sitagliptin in healthy subjects and patients with type 2 diabetes. Furthermore, the investigators want to investigate whether the current clinical dose of 100 mg of sitagliptin is sufficient to inhibit both the plasma and the endothelial activity of the enzyme dipeptidyl peptidase 4.

Conditions

Interventions

DRUG

sitagliptin

In randomized order: Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion

DRUG

Placebo

Day 4: placebo tablet

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD PhD · Gentofte Hospital

  • Tina Vilsbøll, MD DMSc · Gentofte Hospital

  • Asger Lund, MD · Gentofte Hospital

  • Camilla Andersen, Med.stud. · Gentofte Hospital

  • Jens Juul Holst, MD DMSc · Institute of biomedical sciences, University of Copenhagen

  • Emilie Skytte Andersen, Med.stud. · Gentofte Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02192853 on ClinicalTrials.gov